All patients
Age < 65y (younger) Age > 65y ECOG 0 ECOG 1 PD-L1 < 1% PD-L1 > 1% RAS mutant RAS wild type
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
colorectal cancer (CRC), atezolizumab alone vs. regorafenib, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results IMblaze-370 (A ; all population), 2019 1.00 [0.73; 1.37]
1.00 [0.73 ; 1.37 ] IMblaze-370 (A ; all population), 2019 1 0% 180 NA not evaluable progression or deaths (PFS)detailed results IMblaze-370 (A ; all population), 2019 1.39 [1.00; 1.94]
1.39 [1.00 ; 1.94 ] IMblaze-370 (A ; all population), 2019 1 0% 180 NA not evaluable objective responses (ORR)detailed results IMblaze-370 (A ; all population), 2019 1.00 [0.14; 7.26]
1.00 [0.14 ; 7.26 ] IMblaze-370 (A ; all population), 2019 1 0% 180 NA not evaluable AE (any grade)detailed results IMblaze-370 (A ; all population), 2019 0.62 [0.18; 2.22]
0.62 [0.18 ; 2.22 ] IMblaze-370 (A ; all population), 2019 1 0% 170 NA not evaluable AE (grade 3-4)detailed results IMblaze-370 (A ; all population), 2019 0.33 [0.18; 0.63]
0.33 [0.18 ; 0.63 ] IMblaze-370 (A ; all population), 2019 1 0% 170 NA not evaluable AE leading to death (grade 5)detailed results IMblaze-370 (A ; all population), 2019 0.22 [0.01; 4.90]
0.22 [0.01 ; 4.90 ] IMblaze-370 (A ; all population), 2019 1 0% 170 NA not evaluable AE leading to treatment discontinuation (any grade)detailed results IMblaze-370 (A ; all population), 2019 0.49 [0.14; 1.72]
0.49 [0.14 ; 1.72 ] IMblaze-370 (A ; all population), 2019 1 0% 170 NA not evaluable SAE (any grade)detailed results IMblaze-370 (A ; all population), 2019 0.69 [0.32; 1.48]
0.69 [0.32 ; 1.48 ] IMblaze-370 (A ; all population), 2019 1 0% 170 NA not evaluable STRAE (any grade)detailed results IMblaze-370 (A ; all population), 2019 0.67 [0.24; 1.88]
0.67 [0.24 ; 1.88 ] IMblaze-370 (A ; all population), 2019 1 0% 170 NA not evaluable TRAE (any grade)detailed results IMblaze-370 (A ; all population), 2019 0.05 [0.01; 0.16]
0.05 [0.01 ; 0.16 ] IMblaze-370 (A ; all population), 2019 1 0% 170 NA not evaluable TRAE (grade 3-4)detailed results IMblaze-370 (A ; all population), 2019 0.12 [0.05; 0.26]
0.12 [0.05 ; 0.26 ] IMblaze-370 (A ; all population), 2019 1 0% 170 NA not evaluable TRAE leading to death (grade 5)detailed results IMblaze-370 (A ; all population), 2019 0.44 [0.01; 13.33]
0.44 [0.01 ; 13.33 ] IMblaze-370 (A ; all population), 2019 1 0% 170 NA not evaluable Increased lipase level TRAE (grade 3-4)detailed results IMblaze-370 (A ; all population), 2019 0.89 [0.05; 14.43]
0.89 [0.05 ; 14.43 ] IMblaze-370 (A ; all population), 2019 1 0% 170 NA not evaluable hepatitis (Autoimmune) AE (grade 3-4)detailed results IMblaze-370 (A ; all population), 2019 3.61 [0.16; 81.33]
3.61 [0.16 ; 81.33 ] IMblaze-370 (A ; all population), 2019 1 0% 170 NA not evaluable Abdominal pain AE (grade 3-4)detailed results IMblaze-370 (A ; all population), 2019 1.19 [0.26; 5.50]
1.19 [0.26 ; 5.50 ] IMblaze-370 (A ; all population), 2019 1 0% 170 NA not evaluable Acute kidney injury AE (grade 3-4)detailed results IMblaze-370 (A ; all population), 2019 0.89 [0.02; 45.29]
0.89 [0.02 ; 45.29 ] IMblaze-370 (A ; all population), 2019 1 0% 170 NA not evaluable Anaemia AE (grade 3-4)detailed results IMblaze-370 (A ; all population), 2019 0.22 [0.01; 4.90]
0.22 [0.01 ; 4.90 ] IMblaze-370 (A ; all population), 2019 1 0% 170 NA not evaluable Arthralgia AE (grade 3-4)detailed results IMblaze-370 (A ; all population), 2019 0.44 [0.01; 13.33]
0.44 [0.01 ; 13.33 ] IMblaze-370 (A ; all population), 2019 1 0% 170 NA not evaluable Asthenia AE (grade 3-4)detailed results IMblaze-370 (A ; all population), 2019 1.80 [0.16; 20.18]
1.80 [0.16 ; 20.18 ] IMblaze-370 (A ; all population), 2019 1 0% 170 NA not evaluable Back pain AE (grade 3-4)detailed results IMblaze-370 (A ; all population), 2019 5.48 [0.27; 111.16]
5.48 [0.27 ; 111.16 ] IMblaze-370 (A ; all population), 2019 1 0% 170 NA not evaluable Colitis AE (grade 3-4)detailed results IMblaze-370 (A ; all population), 2019 1.79 [0.06; 53.98]
1.79 [0.06 ; 53.98 ] IMblaze-370 (A ; all population), 2019 1 0% 170 NA not evaluable Constipation AE (grade 3-4)detailed results IMblaze-370 (A ; all population), 2019 0.89 [0.02; 45.29]
0.89 [0.02 ; 45.29 ] IMblaze-370 (A ; all population), 2019 1 0% 170 NA not evaluable Cough AE (grade 3-4)detailed results IMblaze-370 (A ; all population), 2019 0.89 [0.02; 45.29]
0.89 [0.02 ; 45.29 ] IMblaze-370 (A ; all population), 2019 1 0% 170 NA not evaluable Decreased appetite AE (grade 3-4)detailed results IMblaze-370 (A ; all population), 2019 0.22 [0.01; 4.90]
0.22 [0.01 ; 4.90 ] IMblaze-370 (A ; all population), 2019 1 0% 170 NA not evaluable Dermatitis acneiform AE (grade 3-4)detailed results IMblaze-370 (A ; all population), 2019 0.89 [0.02; 45.29]
0.89 [0.02 ; 45.29 ] IMblaze-370 (A ; all population), 2019 1 0% 170 NA not evaluable Diarrhoea AE (grade 3-4)detailed results IMblaze-370 (A ; all population), 2019 0.17 [0.02; 1.47]
0.17 [0.02 ; 1.47 ] IMblaze-370 (A ; all population), 2019 1 0% 170 NA not evaluable Dysgeusia AE (grade 3-4)detailed results IMblaze-370 (A ; all population), 2019 0.89 [0.02; 45.29]
0.89 [0.02 ; 45.29 ] IMblaze-370 (A ; all population), 2019 1 0% 170 NA not evaluable Dysphonia AE (grade 3-4)detailed results IMblaze-370 (A ; all population), 2019 0.89 [0.02; 45.29]
0.89 [0.02 ; 45.29 ] IMblaze-370 (A ; all population), 2019 1 0% 170 NA not evaluable Dyspnoea AE (grade 3-4)detailed results IMblaze-370 (A ; all population), 2019 0.44 [0.01; 13.33]
0.44 [0.01 ; 13.33 ] IMblaze-370 (A ; all population), 2019 1 0% 170 NA not evaluable Fatigue AE (grade 3-4)detailed results IMblaze-370 (A ; all population), 2019 0.61 [0.19; 2.02]
0.61 [0.19 ; 2.02 ] IMblaze-370 (A ; all population), 2019 1 0% 170 NA not evaluable Guillain-Barré syndrome AE (grade 3-4)detailed results IMblaze-370 (A ; all population), 2019 0.89 [0.02; 45.29]
0.89 [0.02 ; 45.29 ] IMblaze-370 (A ; all population), 2019 1 0% 170 NA not evaluable Headache AE (grade 3-4)detailed results IMblaze-370 (A ; all population), 2019 0.89 [0.02; 45.29]
0.89 [0.02 ; 45.29 ] IMblaze-370 (A ; all population), 2019 1 0% 170 NA not evaluable Hypertension AE (grade 3-4)detailed results IMblaze-370 (A ; all population), 2019 0.24 [0.06; 0.91]
0.24 [0.06 ; 0.91 ] IMblaze-370 (A ; all population), 2019 1 0% 170 NA not evaluable Increased ALT AE (grade 3-4)detailed results IMblaze-370 (A ; all population), 2019 0.44 [0.01; 13.33]
0.44 [0.01 ; 13.33 ] IMblaze-370 (A ; all population), 2019 1 0% 170 NA not evaluable Infusion-related reaction AE (grade 3-4)detailed results IMblaze-370 (A ; all population), 2019 0.89 [0.02; 45.29]
0.89 [0.02 ; 45.29 ] IMblaze-370 (A ; all population), 2019 1 0% 170 NA not evaluable Intestinal perforation AE (grade 3-4)detailed results IMblaze-370 (A ; all population), 2019 0.44 [0.01; 13.33]
0.44 [0.01 ; 13.33 ] IMblaze-370 (A ; all population), 2019 1 0% 170 NA not evaluable Mucosal inflammation AE (grade 3-4)detailed results IMblaze-370 (A ; all population), 2019 0.89 [0.02; 45.29]
0.89 [0.02 ; 45.29 ] IMblaze-370 (A ; all population), 2019 1 0% 170 NA not evaluable Myalgia AE (grade 3-4)detailed results IMblaze-370 (A ; all population), 2019 0.44 [0.01; 13.33]
0.44 [0.01 ; 13.33 ] IMblaze-370 (A ; all population), 2019 1 0% 170 NA not evaluable Nausea AE (grade 3-4)detailed results IMblaze-370 (A ; all population), 2019 0.89 [0.02; 45.29]
0.89 [0.02 ; 45.29 ] IMblaze-370 (A ; all population), 2019 1 0% 170 NA not evaluable Palmar–plantar erythrodysesthesia syndrome AE (grade 3-4)detailed results IMblaze-370 (A ; all population), 2019 0.04 [0.00; 0.77]
0.04 [0.00 ; 0.77 ] IMblaze-370 (A ; all population), 2019 1 0% 170 NA not evaluable Peripheral neuropathy AE (grade 3-4)detailed results IMblaze-370 (A ; all population), 2019 0.44 [0.01; 13.33]
0.44 [0.01 ; 13.33 ] IMblaze-370 (A ; all population), 2019 1 0% 170 NA not evaluable Peripheral oedema AE (grade 3-4)detailed results IMblaze-370 (A ; all population), 2019 0.89 [0.02; 45.29]
0.89 [0.02 ; 45.29 ] IMblaze-370 (A ; all population), 2019 1 0% 170 NA not evaluable Pneumonitis AE (grade 3-4)detailed results IMblaze-370 (A ; all population), 2019 1.79 [0.06; 53.98]
1.79 [0.06 ; 53.98 ] IMblaze-370 (A ; all population), 2019 1 0% 170 NA not evaluable Pruritus AE (grade 3-4)detailed results IMblaze-370 (A ; all population), 2019 0.89 [0.02; 45.29]
0.89 [0.02 ; 45.29 ] IMblaze-370 (A ; all population), 2019 1 0% 170 NA not evaluable Pyrexia AE (grade 3-4)detailed results IMblaze-370 (A ; all population), 2019 0.89 [0.02; 45.29]
0.89 [0.02 ; 45.29 ] IMblaze-370 (A ; all population), 2019 1 0% 170 NA not evaluable Rash AE (grade 3-4)detailed results IMblaze-370 (A ; all population), 2019 0.44 [0.04; 4.93]
0.44 [0.04 ; 4.93 ] IMblaze-370 (A ; all population), 2019 1 0% 170 NA not evaluable Rash maculopapular AE (grade 3-4)detailed results IMblaze-370 (A ; all population), 2019 0.44 [0.01; 13.33]
0.44 [0.01 ; 13.33 ] IMblaze-370 (A ; all population), 2019 1 0% 170 NA not evaluable Sepsis AE (grade 3-4)detailed results IMblaze-370 (A ; all population), 2019 0.22 [0.01; 4.90]
0.22 [0.01 ; 4.90 ] IMblaze-370 (A ; all population), 2019 1 0% 170 NA not evaluable Stomatitis AE (grade 3-4)detailed results IMblaze-370 (A ; all population), 2019 0.89 [0.02; 45.29]
0.89 [0.02 ; 45.29 ] IMblaze-370 (A ; all population), 2019 1 0% 170 NA not evaluable Thrombocytopenia AE (grade 3-4)detailed results IMblaze-370 (A ; all population), 2019 0.89 [0.02; 45.29]
0.89 [0.02 ; 45.29 ] IMblaze-370 (A ; all population), 2019 1 0% 170 NA not evaluable Vomiting AE (grade 3-4)detailed results IMblaze-370 (A ; all population), 2019 0.89 [0.02; 45.29]
0.89 [0.02 ; 45.29 ] IMblaze-370 (A ; all population), 2019 1 0% 170 NA not evaluable Weight decreased AE (grade 3-4)detailed results IMblaze-370 (A ; all population), 2019 0.89 [0.02; 45.29]
0.89 [0.02 ; 45.29 ] IMblaze-370 (A ; all population), 2019 1 0% 170 NA not evaluable 0.0 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-05 09:39 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 126,385,183,384,137,138
- treatments: 361